Mesothelin-Expressing TumorsPhase 1NCT06623396Papers
M28z1XXPD1DNR CAR
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
What the film says
This trial is for adults with hormone receptor positive, HER2 low or HER2 ultralow metastatic breast cancer that has grown despite a CDK4/6 inhibitor and hormone therapy.
The idea: combine two drugs. Elacestrant is a pill that breaks down the estrogen receptor. Trastuzumab deruxtecan is an antibody drug conjugate that carries chemotherapy to cells with HER2 and is given by vein.
The study looks at safety and how well the combination works.
This phase 1 and 2 study plans 65 patients. At Dana-Farber Cancer Institute in Boston, Kristina Fanucci leads it.
Public record; not medical advice.
Sources behind this film
Adults; HR+ HER2-low/ultralow MBC resistant to CDK4/6i and endocrine; Elacestrant pill; SERD; T-DXd antibody drug conjugate by vein; Safety and efficacy (+1 more lines)
The drug
Selective estrogen receptor degrader (SERD), film-coated tablet, taken orally per protocol.
HER2-directed antibody-drug conjugate, vial, via intravenous (into the vein) infusion per standard of care
This phase Ib/II, open-label, single-arm, investigator-initiated study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy. This is a Phase I/II clinical trial.
The study
The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy.
The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Trastuzumab deruxtecan (a type of standard of care antibody drug conjugate)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.